20 studies found for:    Open Studies | "Thymus Neoplasms"
Show Display Options
Rank Status Study
1 Recruiting Adjuvant Radiotherapy for Stage II/III Thymoma After Complete Resection
Condition: Thymoma
Intervention: Radiation: adjuvant radiotherapy
2 Recruiting Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma
Condition: Thymoma
Intervention: Radiation: radiotherapy
3 Recruiting A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas
Condition: Thymoma
Intervention: Drug: BKM120
4 Recruiting Study of Chemoradiotherapy for Inoperable Locally Advanced (Stage Ⅲ/Ⅳa) Thymoma or Thymic Carcinoma
Condition: Thymoma and Thymic Carcinoma
Intervention: Radiation: concurrent radiochemotherapy
5 Recruiting Regulation of LncRNA For Breg in Patients With Thymoma and Autoimmune Diseases
Conditions: Thymoma;   Autoimmune Disease
Intervention:
6 Recruiting Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma
Condition: Thymoma and Thymic Carcinoma
Interventions: Drug: Cisplatin;   Drug: Etoposide;   Radiation: radiotherapy
7 Recruiting Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
Conditions: Thymoma;   Thymic Carcinoma;   Clinical Masaoka Stage II to IVA
Intervention: Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
8 Recruiting Rapid Autopsy and Procurement of Non-Small Cell Lung Cancer Tissue
Conditions: Thymus Tumors;   Mesothelioma;   Non- Small Cell Lung Cancer;   Small Cell Lung Cancer
Intervention:
9 Recruiting French National Observatory of Patients With Thymic Epithelial Tumor
Condition: Thymic Epithelial Tumor
Intervention:
10 Not yet recruiting A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
Condition: Thymic Epithelial Tumors
Intervention: Drug: Pembrolizumab
11 Recruiting Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Esophageal Neoplasms;   Lung Neoplasms;   Mesothelioma;   Thymus Neoplasms;   Neoplasms, Germ Cell and Embryonal
Intervention: Drug: Mithramycin
12 Recruiting A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: Sunitinib
13 Recruiting MK-3475 in Patients With Thymic Carcinoma
Condition: Thymic Carcinoma
Intervention: Drug: MK-3475
14 Recruiting Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Peritoneal Malignant Mesothelioma;   Advanced Pleural Malignant Mesothelioma;   Advanced Solid Neoplasm;   Recurrent Peritoneal Malignant Mesothelioma;   Recurrent Pleural Malignant Mesothelioma;   Recurrent Solid Neoplasm;   Stage III Non-Small Cell Lung Cancer;   Stage III Ovarian Cancer;   Stage III Pleural Mesothelioma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Non-Small Cell Lung Cancer;   Stage IV Ovarian Cancer;   Stage IV Pleural Mesothelioma;   Thymoma;   Unresectable Solid Neoplasm
Interventions: Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Drug: Methoxyamine;   Drug: Pemetrexed Disodium;   Other: Pharmacological Study
15 Recruiting Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
Conditions: Carcinoma, Non-Small-Cell Lung;   Mesothelioma;   Bladder Cancer;   Ovarian Cancer;   Peritoneal Cancer;   Thymoma;   Thymus Cancer;   Uterine Cervical Cancer
Interventions: Drug: Bosutinib;   Drug: Pemetrexed
16 Recruiting Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Conditions: Carcinoma, Non-Small-Cell Lung;   Carcinoma, Small Cell Lung;   Carcinoma, Thymic
Interventions: Drug: AZD6244;   Drug: MK-2206;   Drug: Lapatinib;   Drug: Erlotinib;   Drug: Sunitinib;   Procedure: Molecular Profiling
17 Recruiting Cancer Research Repository for Individuals With Cancer Diagnosis, High Risk Individuals, and Individuals With No History of Cancer (Control)
Conditions: Pancreatic Cancer;   Thyroid Cancer;   Lung Cancer;   Esophageal Cancer;   Thymus Cancer;   Colon Cancer;   Rectal Cancer;   GIST;   Anal Cancer;   Bile Duct Cancer;   Duodenal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Liver Cancer;   Small Intestine Cancer;   Peritoneal Surface Malignancies;   Familial Adenomatous Polyposis;   Lynch Syndrome;   Bladder Cancer;   Kidney Cancer;   Penile Cancer;   Prostate Cancer;   Testicular Cancer;   Ureter Cancer;   Urethral Cancer;   Hypopharyngeal Cancer;   Laryngeal Cancer;   Lip Cancer;   Oral Cavity Cancer;   Nasopharyngeal Cancer;   Oropharyngeal Cancer;   Paranasal Sinus Cancer;   Nasal Cavity Cancer;   Salivary Gland Cancer;   Skin Cancer;   CNS Tumor;   CNS Cancer;   Mesothelioma;   Breastcancer;   Leukemia;   Melanoma;   Sarcoma;   Unknown Primary Tumor;   Multiple Myeloma;   Ovarian Cancer;   Endometrial Cancer;   Vaginal Cancer
Intervention:
18 Recruiting Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Conditions: Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Extrapulmonary Small Cell Cancer;   Pulmonary Neuroendocrine Tumors;   Thymic Epithelial Tumors
Intervention:
19 Recruiting CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis
Condition: Candidiasis, Chronic Mucocutaneous
Intervention: Drug: Amphotericin B
20 Recruiting Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare Tumors
Condition: Advanced Cancers
Interventions: Drug: Pembrolizumab;   Behavioral: Phone Call Follow-Up

Study has passed its completion date and status has not been verified in more than two years.